Search research articles
Contact Us
Filters
Showing results (1-10 of 109) with videos related to
Page
of 11
Sort By:
Preventive Medicine
|
July 1, 2020
Response to McNamara's comment on "Cost-utility of colorectal cancer screening at age 40 years old for average-risk patients" by Azad et al
Ira L Leeds, Nilofer S Azad
Cancers
|
April 14, 2025
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Kai-Li Liang, Nilofer S Azad
Nature Reviews. Gastroenterology & Hepatology
|
June 14, 2024
Unlocking the promise of RAS inhibition in pancreatic cancer
Saurav D Haldar, Nilofer S Azad
Chinese Clinical Oncology
|
February 4, 2020
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
Christopher D Jakubowski, Nilofer S Azad
Oncology (Williston Park, N.Y.)
|
April 8, 2014
The utility of molecular testing in colorectal cancer: the promise needs progress
Nilofer S Azad, Luis A Diaz
Therapeutic Advances in Medical Oncology
|
March 7, 2024
Immunotherapy for the treatment of biliary tract cancer: an evolving landscape
Helen Catherine Wilbur, Nilofer S Azad
The Lancet. Oncology
|
March 6, 2020
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Eric S Christenson, Elizabeth Jaffee, Nilofer S Azad
Drug Discovery Today
|
September 11, 2007
The ongoing evolution of proteomics in malignancy
Amit S Dhamoon, Elise C Kohn, Nilofer S Azad
Hepatology (Baltimore, Md.)
|
January 24, 2024
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations
H Catherine Wilbur, Heloisa P Soares, Nilofer S Azad
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
Page
of 11
Search research articles
Search
Showing results (1-10 of 109) with videos related to
Sort By:
Page
of 11
Preventive Medicine
|
July 1, 2020
Response to McNamara's comment on "Cost-utility of colorectal cancer screening at age 40 years old for average-risk patients" by Azad et al
Ira L Leeds, Nilofer S Azad
Cancers
|
April 14, 2025
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Kai-Li Liang, Nilofer S Azad
Nature Reviews. Gastroenterology & Hepatology
|
June 14, 2024
Unlocking the promise of RAS inhibition in pancreatic cancer
Saurav D Haldar, Nilofer S Azad
Chinese Clinical Oncology
|
February 4, 2020
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
Christopher D Jakubowski, Nilofer S Azad
Oncology (Williston Park, N.Y.)
|
April 8, 2014
The utility of molecular testing in colorectal cancer: the promise needs progress
Nilofer S Azad, Luis A Diaz
Therapeutic Advances in Medical Oncology
|
March 7, 2024
Immunotherapy for the treatment of biliary tract cancer: an evolving landscape
Helen Catherine Wilbur, Nilofer S Azad
The Lancet. Oncology
|
March 6, 2020
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Eric S Christenson, Elizabeth Jaffee, Nilofer S Azad
Drug Discovery Today
|
September 11, 2007
The ongoing evolution of proteomics in malignancy
Amit S Dhamoon, Elise C Kohn, Nilofer S Azad
Hepatology (Baltimore, Md.)
|
January 24, 2024
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations
H Catherine Wilbur, Heloisa P Soares, Nilofer S Azad
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
Page
of 11